Description Results NMA

Total mortality 1.24 [1.02; 1.51]

Sudden death 1.57 [1.14; 2.17]

Cardiac death 1.30 [1.06; 1.60]

Vertigo 1.90 [1.40; 2.57]

Myocardial infarction (fatal & non fatal) 5.64 [0.68; 46.66]

Worsening heart failure (requiring intervention) 1.88 [0.65; 5.46]

Transplantation 0.63 [0.11; 3.73]

Arrhythmia 1.22 [0.95; 1.56]

Total mortality 2.33 [0.94; 5.80]

Myocardial infarction (fatal & non fatal) ∞ [NaN; ∞]

Cardiac death 1.87 [0.72; 4.80]

Worsening heart failure (requiring intervention) 0.87 [0.57; 1.34]

Arrhythmia 1.87 [0.91; 3.81]

Vertigo 2.05 [0.74; 5.72]

Milrinone 40mg/d (n=561)

vs.

placebo (n=527)

double blind

Parallel groups

Sample size: 561/527

Primary endpoint: Total mortality

FU duration: 20 months

Milrinone <40mg/d (n=119)

vs.

placebo (n=111)

double blind

Parallel groups

Sample size: 119/111

Primary endpoint: none

FU duration: 3 months